AR095430A1 - Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr - Google Patents
Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfrInfo
- Publication number
- AR095430A1 AR095430A1 ARP140100975A ARP140100975A AR095430A1 AR 095430 A1 AR095430 A1 AR 095430A1 AR P140100975 A ARP140100975 A AR P140100975A AR P140100975 A ARP140100975 A AR P140100975A AR 095430 A1 AR095430 A1 AR 095430A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- heteroaryl
- haloalkyl
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 21
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- -1 -S (O) nNR6R7 Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas que los contienen, y su uso en terapia de enfermedades que responden a inhibición de FGFR, por ejemplo, cáncer. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde X es CH₂, Y es seleccionado de CH₂, O ó S(O)₂; ó X e Y junto con el enlace entre ellos forman -CH=CH- ó -CºC-; G es N ó CH; R¹ es arilo o heteroarilo, cada uno está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de halo, -NR⁶R⁷, -OR⁸, -S(O)ₙR⁹, -(CH₂)ʳ-C(O)R¹⁰, -CN, -C(O)NR⁶R⁷, -NR⁶C(O)R¹⁰, -NR⁶S(O)ₙR⁹, -NR⁶S(O)ₙNR¹¹R¹², -NR⁶C(O)OR⁸, -NR⁶C(O)NR¹¹R¹², -NO₂, -S(O)ₙNR⁶R⁷, oxo, alquilo opcionalmente sustituido, -(CH₂)ₚ-cicloalquilo opcionalmente sustituido, -(CH₂)ₘ-heterociclilo opcionalmente sustituido, -(CH₂)q-heteroarilo opcionalmente sustituido, alquenilo opcionalmente sustituido, y alquinilo opcionalmente sustituido; R² es independientemente elegido de alquilo C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, o cicloalquilo C₃₋₈ opcionalmente sustituido; R³, R⁴ son elegidos independientemente de hidrógeno, halógeno, -CN, o alquilo C₁₋₆ opcionalmente sustituido; R⁵ es alquilo C₁₋₆, ó R³ y R⁵ junto con el átomo de O al cual R⁵ está unido y el enlace entre ellos forman un anillo heterocíclico que contiene oxígeno de 5 ó 6 miembros; n es 1 ó 2; m, p, q y r son elegidos independientemente de 0, 1, 2, 3, 4, 5, 6; R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ y R¹² son independientemente seleccionados de hidrógeno, alquilo, cicloalquilo, arilo, heteroarilo, heterociclilo, cada uno de los cuales excepto el hidrógeno, está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados de halo, hidroxilo, mercapto, oxo, alquilo, cicloalquilo, heterociclilo, amino opcionalmente sustituido, y amida opcionalmente sustituida, en donde cada grupo opcionalmente sustituido anterior para los cuales el(los) sustituyente(s) no está(n) específicamente designado(s), pueden estar no sustituidos o independientemente sustituidos con uno o más, tal como uno, dos o tres, sustituyentes independientemente seleccionados de alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo, arilo, heterociclilo, heteroarilo, aril-alquil C₁₋₆-, heteroaril-alquil C₁₋₆-, haloalquil C₁₋₆-, -O-alquilo C₁₋₆, -O-alquenilo C₂₋₆, -O-alquil C₁₋₆fenilo, -alquil C₁₋₆-OH, -alquil C₁₋₆-SH, -alquil C₁₋₆-O-alquilo C₁₋₆, -O-haloalquilo C₁₋₆, halo, -OH, mercapto, -NH₂, -alquil C₁₋₆-NH₂, -N(alquilo C₁₋₆)₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)(alquil C₁₋₆fenilo), -NH(alquil C₁₋₆fenilo), ciano, nitro, oxo, -C(O)-OH, -C(O)O-alquilo C₁₋₆, -CON(alquilo C₁₋₆)₂, -CONH(alquilo C₁₋₆), -CONH₂, -NHC(O)(alquilo C₁₋₆), -NHC(O)(fenilo), -N(alquilo C₁₋₆)C(O)(alquilo C₁₋₆), -N(alquilo C₁₋₆)C(O)(fenilo), -C(O)alquilo C₁₋₆, -C(O)alquil C₁₋₆fenilo, -C(O)haloalquilo C₁₋₆, -OC(O)alquilo C₁₋₆, -S(O)₂-alquilo C₁₋₆, -S(O)-alquilo C₁₋₆, -S(O)₂-fenilo, -S(O)₂-haloalquilo C₁₋₆, -S(O)₂NH₂, -S(O)₂NH(alquilo C₁₋₆), -S(O)₂NH(fenilo), -NHS(O)₂(alquilo C₁₋₆), -NHS(O)₂(fenilo), y -NHS(O)₂(haloalquilo C₁₋₆).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/072690 WO2014139145A1 (en) | 2013-03-15 | 2013-03-15 | Novel pyrimidine and pyridine compounds and usage thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095430A1 true AR095430A1 (es) | 2015-10-14 |
Family
ID=51535826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100975A AR095430A1 (es) | 2013-03-15 | 2014-03-13 | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20160052926A1 (es) |
| EP (1) | EP2970120B1 (es) |
| JP (1) | JP6109969B2 (es) |
| KR (1) | KR101697982B1 (es) |
| CN (1) | CN105143185B (es) |
| AR (1) | AR095430A1 (es) |
| AU (1) | AU2014231437B2 (es) |
| BR (1) | BR112015020772B1 (es) |
| CA (1) | CA2900748C (es) |
| CL (1) | CL2015002520A1 (es) |
| CY (1) | CY1121804T1 (es) |
| DK (1) | DK2970120T3 (es) |
| EA (1) | EA028654B1 (es) |
| ES (1) | ES2697697T3 (es) |
| HR (1) | HRP20181906T1 (es) |
| IL (1) | IL240790B (es) |
| LT (1) | LT2970120T (es) |
| MX (1) | MX363397B (es) |
| MY (1) | MY192641A (es) |
| NZ (1) | NZ711460A (es) |
| PE (1) | PE20151601A1 (es) |
| PH (1) | PH12015502047B1 (es) |
| PL (1) | PL2970120T3 (es) |
| PT (1) | PT2970120T (es) |
| RS (1) | RS58136B1 (es) |
| SG (1) | SG11201506280SA (es) |
| SI (1) | SI2970120T1 (es) |
| SM (1) | SMT201800596T1 (es) |
| TW (1) | TWI618698B (es) |
| UA (1) | UA113470C2 (es) |
| WO (2) | WO2014139145A1 (es) |
| ZA (1) | ZA201505999B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014072714A1 (en) | 2012-11-07 | 2014-05-15 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ES2790419T3 (es) | 2013-01-15 | 2020-10-27 | Incyte Holdings Corp | Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM |
| WO2014181137A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2018072707A1 (zh) * | 2016-10-18 | 2018-04-26 | 保诺科技（北京）有限公司 | 芳香族醚类衍生物、其制备方法及其在医药上的应用 |
| US11008292B2 (en) | 2016-11-17 | 2021-05-18 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | FGFR4 inhibitor and preparation method and use thereof |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| CN108570032B (zh) * | 2017-03-09 | 2021-04-02 | 华东理工大学 | 新型罗丹明染料及其在抗致病菌中的应用 |
| CN107382836A (zh) * | 2017-08-04 | 2017-11-24 | 吴赣药业（苏州）有限公司 | 一种1‑(4‑氨基苯基)‑1h‑吡啶‑2‑酮的制备方法 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| AU2020367905A1 (en) | 2019-10-14 | 2022-04-21 | Hutchison Medipharma Limited | The salts of a compound and the crystalline forms thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004021558D1 (de) * | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| WO2005002673A1 (en) * | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
| US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| KR20070113288A (ko) * | 2005-03-16 | 2007-11-28 | 탈자진 인코포레이티드 | 피리미딘 화합물 및 사용 방법 |
| WO2007056075A2 (en) * | 2005-11-02 | 2007-05-18 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
| US8030487B2 (en) * | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
| EP2081928B1 (en) | 2006-11-10 | 2014-02-26 | Bristol-Myers Squibb Company | Pyrrolo-pyridine kinase inhibitors |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| BRPI0914233A2 (pt) * | 2008-06-19 | 2015-11-03 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença |
| ES2650810T3 (es) * | 2009-01-28 | 2018-01-22 | Karus Therapeutics Limited | Isósteros de Scriptaid y su uso en terapia |
| BR112014018868B1 (pt) * | 2012-02-28 | 2021-02-09 | Astellas Pharma Inc. | composto heterocíclico aromático contendo nitrogênio, composição farmacêutica compreendendo dito composto e uso do mesmo |
| PT2824181T (pt) | 2012-03-08 | 2018-12-20 | Astellas Pharma Inc | Novo produto de fusão de fgfr3 |
-
2013
- 2013-03-15 WO PCT/CN2013/072690 patent/WO2014139145A1/en not_active Ceased
- 2013-03-15 US US14/775,649 patent/US20160052926A1/en not_active Abandoned
-
2014
- 2014-03-12 TW TW103108613A patent/TWI618698B/zh active
- 2014-03-13 AR ARP140100975A patent/AR095430A1/es active IP Right Grant
- 2014-03-14 AU AU2014231437A patent/AU2014231437B2/en active Active
- 2014-03-14 NZ NZ711460A patent/NZ711460A/en unknown
- 2014-03-14 BR BR112015020772-3A patent/BR112015020772B1/pt active IP Right Grant
- 2014-03-14 EA EA201591301A patent/EA028654B1/ru unknown
- 2014-03-14 SI SI201430969T patent/SI2970120T1/sl unknown
- 2014-03-14 SG SG11201506280SA patent/SG11201506280SA/en unknown
- 2014-03-14 LT LTEP14764299.5T patent/LT2970120T/lt unknown
- 2014-03-14 CA CA2900748A patent/CA2900748C/en active Active
- 2014-03-14 ES ES14764299T patent/ES2697697T3/es active Active
- 2014-03-14 US US14/775,653 patent/US9701680B2/en active Active
- 2014-03-14 PL PL14764299T patent/PL2970120T3/pl unknown
- 2014-03-14 EP EP14764299.5A patent/EP2970120B1/en active Active
- 2014-03-14 PE PE2015001855A patent/PE20151601A1/es active IP Right Grant
- 2014-03-14 MY MYPI2015703158A patent/MY192641A/en unknown
- 2014-03-14 PT PT14764299T patent/PT2970120T/pt unknown
- 2014-03-14 DK DK14764299.5T patent/DK2970120T3/en active
- 2014-03-14 WO PCT/CN2014/073444 patent/WO2014139465A1/en not_active Ceased
- 2014-03-14 CN CN201480015314.7A patent/CN105143185B/zh active Active
- 2014-03-14 HR HRP20181906TT patent/HRP20181906T1/hr unknown
- 2014-03-14 MX MX2015012363A patent/MX363397B/es unknown
- 2014-03-14 RS RS20181394A patent/RS58136B1/sr unknown
- 2014-03-14 UA UAA201509752A patent/UA113470C2/uk unknown
- 2014-03-14 KR KR1020157027380A patent/KR101697982B1/ko active Active
- 2014-03-14 SM SM20180596T patent/SMT201800596T1/it unknown
- 2014-03-14 JP JP2015561928A patent/JP6109969B2/ja active Active
-
2015
- 2015-08-19 ZA ZA2015/05999A patent/ZA201505999B/en unknown
- 2015-08-24 IL IL24079015A patent/IL240790B/en active IP Right Grant
- 2015-09-08 CL CL2015002520A patent/CL2015002520A1/es unknown
- 2015-09-10 PH PH12015502047A patent/PH12015502047B1/en unknown
-
2018
- 2018-11-15 CY CY20181101211T patent/CY1121804T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR112529A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR105575A1 (es) | COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR095351A1 (es) | Inhibidores de histona desacetilasa (hdac) | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR096040A1 (es) | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR095350A1 (es) | Compuestos inhibidores de una histona deacetilasa y composición farmacéutica que los contiene | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR122336A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |